Capricor Therapeutics, Inc. (CAPR)
NASDAQ:CAPR
Want to see CAPR full AI Analyst Report?
CAPR Stock Chart & Stats
$34.70
-$0.36(-2.53%)
At close: 4:00 PM EST
$34.70
-$0.36(-2.53%)
Day’s Range― - ―
52-Week Range$4.30 - $40.37
Previous CloseN/A
Volume187.65K
Average Volume (3M)1.02M
Market Cap
$1.49B
Enterprise Value$1.29B
Total Cash (Recent Filing)$278.61M
Total Debt (Recent Filing)$21.12M
Price to Earnings (P/E)―
Beta2.22
Next Earnings
Aug 12, 2026EPS Estimate
-0.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.32
Shares Outstanding57,911,892
10 Day Avg. Volume854,235
30 Day Avg. Volume1,016,608
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)4.39
Price to Sales (P/S)0.00
P/FCF Ratio-18.45
Enterprise Value/Market Cap0.86
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-30.31
Enterprise Value/Ebitda-11.63
Forecast
1Y Price Target
$53.29Price Target Upside53.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.59
Revenue Forecast (FY)$117.33M
Bulls Say, Bears Say
Bulls Say
Phase 3 Clinical EfficacyRobust, statistically significant Phase 3 efficacy materially de-risks deramiocel’s clinical value proposition. Pivotal data supports regulatory approval likelihood, label strength and long-term payer discussions, providing a durable foundation for commercial opportunity over the next 2–6 months.
Advanced Regulatory PositioningAn active BLA with a defined PDUFA date materially reduces timing uncertainty and creates a clear regulatory path. Ongoing information exchanges with FDA indicate issues are largely technical, which supports a structurally improved approval probability and near-term commercialization planning.
In-house Manufacturing & Scale PlanControl of GMP manufacturing and a documented staged scale plan reduces supply dependency and supports commercial readiness. Combined with a reported ~$279M cash balance providing runway into 2027, this structural setup improves execution prospects for initial launch and validated scale-up through 2027.
Bears Say
Commercial Litigation RiskActive litigation over U.S. distribution creates material, durable uncertainty for launch timing and go-to-market control. Potential remedies (rescission, injunctions, repayment of $50M) could delay commercialization, force alternative rollout strategies, and increase execution risk over several months.
Weak Cash Generation & Persistent LossesPersistent operating losses, negative operating and free cash flow, and recent zero reported revenue mean the company remains funding-intensive. Even with runway into 2027, rising opex and limited self-funding elevate the risk of dilution or non-dilutive monetization needs within a multi-quarter horizon.
Reimbursement & Ultra‑Cold Labeling ConstraintsUltra-cold supply constraints plus unresolved ASP/AMP transfer‑pricing create structural access and reimbursement barriers. These issues can prevent dose stockpiling, complicate hospital logistics, and materially limit uptake and revenue realization even if approved, lasting through initial commercialization phases.
Capricor Therapeutics News
CAPR FAQ
What was Capricor Therapeutics, Inc.’s price range in the past 12 months?
Capricor Therapeutics, Inc. lowest stock price was $4.30 and its highest was $40.37 in the past 12 months.
What is Capricor Therapeutics, Inc.’s market cap?
Capricor Therapeutics, Inc.’s market cap is $1.49B.
When is Capricor Therapeutics, Inc.’s upcoming earnings report date?
Capricor Therapeutics, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 57 days.
How were Capricor Therapeutics, Inc.’s earnings last quarter?
Capricor Therapeutics, Inc. released its earnings results on May 12, 2026. The company reported -$0.59 earnings per share for the quarter, missing the consensus estimate of -$0.507 by -$0.083.
Is Capricor Therapeutics, Inc. overvalued?
According to Wall Street analysts Capricor Therapeutics, Inc.’s price is currently Undervalued.
Does Capricor Therapeutics, Inc. pay dividends?
Capricor Therapeutics, Inc. does not currently pay dividends.
What is Capricor Therapeutics, Inc.’s EPS estimate?
Capricor Therapeutics, Inc.’s EPS estimate is -0.59.
How many shares outstanding does Capricor Therapeutics, Inc. have?
Capricor Therapeutics, Inc. has 57,911,892 shares outstanding.
What happened to Capricor Therapeutics, Inc.’s price movement after its last earnings report?
Capricor Therapeutics, Inc. reported an EPS of -$0.59 in its last earnings report, missing expectations of -$0.507. Following the earnings report the stock price went down -3.775%.
Which hedge fund is a major shareholder of Capricor Therapeutics, Inc.?
Currently, no hedge funds are holding shares in CAPR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Capricor Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$53.29 (53.56% Upside)
$53.29 (53.56% Upside)
Blogger Sentiment
Bullish
CAPR Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 149.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 4.0%
Last 30 Days ▼ 4.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
85.07%
12-Months-Change
Fundamentals
Return on Equity
-59.27%
Trailing 12-Months
Asset Growth
112.19%
Trailing 12-Months
Company Description
Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on pioneering transformative cell and exosome-based therapies to treat and prevent a diverse range of diseases and disorders. Their lead therapeutic, CAP-1002, is an allogeneic cell therapy derived from heart tissue. This candidate has successfully completed its Phase III clinical trial for patients afflicted with late-stage Duchenne muscular dystrophy (DMD). CAP-1002 is simultaneously progressing through Phase II clinical testing to address cytokine storm associated with SARS-CoV-2. Beyond CAP-1002, the company is advancing CAP-2003 through preclinical development, aiming to treat trauma-related injuries and medical conditions. Furthermore, Capricor is developing two vaccine candidates with the potential to prevent COVID-19. Capricor collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, supporting its use in DMD and other indications. The company was established in 2005 and is headquartered in San Diego, California.
CAPR Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong clinical and regulatory progress for deramiocel — statistically significant phase 3 efficacy (primary and cardiac secondary endpoints), robust long-term safety exposure, active BLA review with a clear PDUFA date, in-house manufacturing capabilities and a solid cash runway. Management also articulated a concrete commercialization plan and eligibility for a monetizable Priority Review Voucher. Offsetting these positives are notable near-term risks: an active lawsuit with NS Pharma that creates distribution uncertainty (and potential need to repay $50M), rising operating expenses and no current product revenue, manufacturing labeling constraints for an ultra-cold-chain therapy, and unresolved ASP/AMP payer complexities that could affect access. On balance, the material clinical/regulatory achievements and internal control of manufacturing and cash resources outweigh the legal and commercial execution risks, but the litigation and payer/pricing issues remain important near-term uncertainties.View all CAPR earnings summariesCAPR Stock 12 Month Forecast
Average Price Target
$53.29
▲(53.56% Upside)
Technical Analysis
Ownership Overview
0.93% Insiders
7.75% Mutual Funds
27.28% Other Institutional Investors
54.04% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---